Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Alzheimer'S Disease : JAD|May 21, 2025
Performance of a smell identification test versus the Mini-Mental Status Exam for the detection of dementia and cognitive impairment among persons with cognitive concerns in primary careJosé A Luchsinger, Jeanne A Teresi, Lenfis Valdez, et al.
Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.
The Lancet. Oncology|May 6, 2024
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 studyBob T Li, Funda Meric-Bernstam, Aditya Bardia, et al.
Gynecologic Oncology|January 11, 2024
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trialClaire F Friedman, Anishka D'Souza, Diana Bello Roufai, et al.
Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancerByoung Chul Cho, Melissa Johnson, Jair Bar, et al.
Heart Rhythm|April 4, 2026
Improving Transthyretin cardiac amyloidosis detection from electrocardiograms through Willem AI platformEsther González-López, Ruben Abbou, Rafael López-García, et al.
The Lancet. Oncology|October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion studyChristina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Pageof 4